Skip to content

Study · Observational study · n = 937 · 2020

7 results

Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).

Brown RE, Bech PG, Aronson R

Diabetes, obesity & metabolism13 Jul 2020Cited by 41 (Europe PMC)

PMID32538541 (opens in a new tab)PMCIDPMC7689820 (opens in a new tab)DOI10.1111/dom.14117 (opens in a new tab)PepBankPUB-32538541
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In GLP-1RA-naive adults with type 2 diabetes who started semaglutide in routine care, mean HbA1c fell significantly at 3 to 6 months.

    In plain wordsIn adults with type 2 diabetes starting semaglutide in routine care, HbA1c fell significantly after 3 to 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at 3 to 6 months
    Study

    n = 937

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −1.03%
    mean at 3-6 months

    Source sentences

    Summary
    In the final analytical cohort (n = 937), there was a statistically significant mean ± SD reduction in HbA1c of -1.03 ± 1.24% (11.3 ± 13.6 mmol/mol, P < 0.001)
    1 context sentence
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.
  2. 02HumanObservational studyEfficacy outcome

    In GLP-1RA-naive adults with type 2 diabetes who started semaglutide in routine care, mean body weight fell significantly at 3 to 6 months.

    In plain wordsIn adults with type 2 diabetes starting semaglutide in routine care, body weight fell significantly after 3 to 6 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 3 to 6 months
    Study

    n = 937

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change
    −3.9 kg
    mean

    Source sentences

    Summary
    In the final analytical cohort (n = 937), there was a statistically significant mean ± SD reduction in HbA1c of -1.03 ± 1.24% (11.3 ± 13.6 mmol/mol, P < 0.001) and weight of -3.9 ± 4.0 kg (P < 0.001)
    1 context sentence
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.
  3. 03HumanObservational studySafety outcome

    In adults with type 2 diabetes starting semaglutide in routine care, self-reported hypoglycaemia incidence did not change significantly.

    In plain wordsIn adults with type 2 diabetes starting semaglutide in routine care, reported low blood sugar episodes did not change significantly.

    Peptide
    Semaglutide
    Outcome
    No significant changeSelf-reported hypoglycaemia incidence
    Study

    n = 937

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with no significant change in self-reported incidence of hypoglycaemia.
    1 context sentence
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.
  4. 04HumanObservational studyEfficacy outcome

    HbA1c fell significantly with semaglutide regardless of the number of co-therapies or semaglutide dose.

    In plain wordsHbA1c fell with semaglutide whatever the number of other diabetes drugs or the semaglutide dose.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction across co-therapy number and dose subgroups
    Study

    n = 937

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was a significant reduction in HbA1c
    2 context sentences
    Summary · context
    regardless of number of co-therapies or semaglutide dose.
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.
  5. 05HumanObservational studyEfficacy outcome

    Body weight fell significantly with semaglutide regardless of the number of co-therapies or semaglutide dose.

    In plain wordsBody weight fell with semaglutide whatever the number of other diabetes drugs or the semaglutide dose.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction across co-therapy number and dose subgroups
    Study

    n = 937

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was a significant reduction in HbA1c and weight regardless of number of co-therapies or semaglutide dose.
    1 context sentence
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.
  6. 06HumanObservational studyEfficacy outcome

    Adults using semaglutide 1.0 mg had a significantly greater HbA1c reduction than adults using 0.25 to 0.5 mg.

    In plain wordsAdults using the 1.0 mg semaglutide dose had a bigger HbA1c drop than adults using 0.25 to 0.5 mg.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c reduction, 1.0 mg versus 0.25-0.5 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 0.25 to 0.5 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mgAs given in this study (human).

    Measurements

    Between-group HbA1c difference
    −0.24%
    1.0 mg vs 0.25-0.5 mg

    Source sentences

    Summary
    However, adults using the 1.0-mg dose had a significantly greater reduction in HbA1c compared to adults using the 0.25- to 0.5-mg dose (between-group difference - 0.24 ± 0.06%, 2.6 ± 0.7 mmol/mol; P < 0.001).
    1 context sentence
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.
  7. 07HumanObservational studyEfficacy outcome

    In adults on basal-bolus insulin, median total daily insulin dose was significantly lower after adding semaglutide.

    In plain wordsIn adults on basal-bolus insulin, the daily insulin dose was lower after adding semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal daily insulin dose in basal-bolus users
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median total daily insulin dose
    0.82 U/kg
    after semaglutide
    Median total daily insulin dose
    0.93 U/kg
    before semaglutide

    Source sentences

    Summary
    Adults using basal-bolus therapy required a significantly lower median total daily dose of insulin after adding semaglutide (0.82 vs. 0.93 U/kg; P < 0.001).
    1 context sentence
    Summary · context
    Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.